Literature DB >> 31019943

Significant association of CD4+CD25+Foxp3+ regulatory T cells with clinical findings in patients with systemic lupus erythematosus.

Xiaofan Yang1, Weiwen Wang2, Juan Xu1, Ming-Shun Zhang1, Huanping Mei3, Youxuan Shen3, Miao-Jia Zhang3, Xiaohui Ji1, Huijuan Wang1.   

Abstract

BACKGROUND: Regulatory T (Treg) cells are one of the important mechanisms in maintaining self-tolerance and immune homeostasis. CD4+CD25+Foxp3+Treg is considered to have a role in the pathogenesis of systemic lupus erythematosus (SLE). However, the data reported is controversial, and a conclusive result has not been given thus far. The aim of the present study is to evaluate the role of CD4+Treg in SLE further.
METHODS: The peripheral blood T cells (PBMCs) from patients with SLE and healthy controls were isolated, and followed by the isolation of CD3+T cells. The PBMCs were tested for the expressions of CD25 and Foxp3 molecules on the surface of CD4+T cells, and CD3+T cells were tested for their cytokine expressions including IFN-γ, TGF-β, and IL-10, with the method of flow cytometry. The correlations of test results with clinical features of the disease were evaluated by linear correlation analysis.
RESULTS: CD4+CD25+ Foxp3+Treg decreased in SLE patients and was correlated with the SLE Disease Activity Index (SLEDAI), and a few immunological abnormalities, including anti-dsDNA antibody positive, IgG increase and C3 decrease, and types of tissue damage, including leukocytopenia and kidney damage. IFN-γ+ cells in the CD4+CD25+T subset fresh-isolated from SLE patients increased slightly, but IFN-γ-producing response to stimulation in CD4+CD25+T subset of SLE decreased. The number of TGF-β-producing cells in the CD4+CD25+T subset from SLE patients also decreased. While the percentages of CD4+CD25+IL-10+T subset in the CD3+T cells increased in SLE, however, these changes of cytokine expressions did not show any significant correlations with SLEDAI.
CONCLUSIONS: There is clear and definite evidence from the present study indicating the important role of CD4+CD25+Foxp3+Treg in the pathogenesis of SLE, for the abnormalities in functional cytokine productions of the CD4+CD25+ T subset, and for the feasibility of a CD4+CD25+Foxp3+Treg- based immunotherapy in SLE.

Entities:  

Keywords:  Foxp3; cytokine; regulatory T cell (Treg); systemic lupus erythematosus (SLE)

Year:  2019        PMID: 31019943      PMCID: PMC6462640          DOI: 10.21037/atm.2019.01.38

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  35 in total

1.  Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms.

Authors:  Ming O Li; Shomyseh Sanjabi; Richard A Flavell
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

2.  Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.

Authors:  Xavier Valencia; Cheryl Yarboro; Gabor Illei; Peter E Lipsky
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

3.  Regulatory T cells in patients with systemic lupus erythematosus.

Authors:  Brenda Alvarado-Sánchez; Berenice Hernández-Castro; Diana Portales-Pérez; Lourdes Baranda; Esther Layseca-Espinosa; Carlos Abud-Mendoza; Ana C Cubillas-Tejeda; Roberto González-Amaro
Journal:  J Autoimmun       Date:  2006-08-04       Impact factor: 7.094

4.  Global natural regulatory T cell depletion in active systemic lupus erythematosus.

Authors:  Makoto Miyara; Zahir Amoura; Christophe Parizot; Cécile Badoual; Karim Dorgham; Salim Trad; Dominique Nochy; Patrice Debré; Jean-Charles Piette; Guy Gorochov
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 5.  FOXP3 modifies the phenotypic and functional properties of regulatory T cells.

Authors:  Daniel J Campbell; Steven F Ziegler
Journal:  Nat Rev Immunol       Date:  2007-04       Impact factor: 53.106

6.  Systemic lupus erythematosus disease activity index 2000.

Authors:  Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

7.  Quantification of regulatory T cells in patients with systemic lupus erythematosus.

Authors:  Jose C Crispin; Araceli Martínez; Jorge Alcocer-Varela
Journal:  J Autoimmun       Date:  2003-11       Impact factor: 7.094

8.  Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus.

Authors:  M-F Liu; C-R Wang; L-L Fung; C-R Wu
Journal:  Scand J Immunol       Date:  2004-02       Impact factor: 3.487

9.  Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo.

Authors:  Kathryn J Wood; Birgit Sawitzki
Journal:  Trends Immunol       Date:  2006-03-09       Impact factor: 16.687

Review 10.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  4 in total

1.  Association between systemic lupus erythematosus and lung cancer: results from a pool of cohort studies and Mendelian randomization analysis.

Authors:  Haoxin Peng; Caichen Li; Xiangrong Wu; Yaokai Wen; Jinsheng Lin; Hengrui Liang; Ran Zhong; Jun Liu; Jianxing He; Wenhua Liang
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

2.  Protective effect of FOXP3-mediated miR-146b-5p/Robo1/NF-κB system on lipopolysaccharide-induced acute lung injury in mice.

Authors:  Jiang Zhu; Gaoli Chen
Journal:  Ann Transl Med       Date:  2020-12

3.  Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus.

Authors:  Butsabong Lerkvaleekul; Nopporn Apiwattanakul; Kanchana Tangnararatchakit; Nisa Jirapattananon; Supanart Srisala; Soamarat Vilaiyuk
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

4.  New biomarkers in SLE: from bench to bedside.

Authors:  Riccardo Capecchi; Ilaria Puxeddu; Federico Pratesi; Paola Migliorini
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.